CN105358149A - 粉防己碱家族的药物制剂和方法 - Google Patents

粉防己碱家族的药物制剂和方法 Download PDF

Info

Publication number
CN105358149A
CN105358149A CN201480028296.6A CN201480028296A CN105358149A CN 105358149 A CN105358149 A CN 105358149A CN 201480028296 A CN201480028296 A CN 201480028296A CN 105358149 A CN105358149 A CN 105358149A
Authority
CN
China
Prior art keywords
tetrandrine
family
pharmaceutical
tetrandrine family
diacid salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480028296.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·D·卡罗尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CBA Pharma Inc
Original Assignee
CBA Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CBA Pharma Inc filed Critical CBA Pharma Inc
Publication of CN105358149A publication Critical patent/CN105358149A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480028296.6A 2013-03-15 2014-03-06 粉防己碱家族的药物制剂和方法 Pending CN105358149A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792849P 2013-03-15 2013-03-15
US61/792,849 2013-03-15
PCT/US2014/021195 WO2014149848A1 (en) 2013-03-15 2014-03-06 Tetrandrine family pharmaceutical formulations and method

Publications (1)

Publication Number Publication Date
CN105358149A true CN105358149A (zh) 2016-02-24

Family

ID=51529969

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480028296.6A Pending CN105358149A (zh) 2013-03-15 2014-03-06 粉防己碱家族的药物制剂和方法

Country Status (7)

Country Link
US (4) US9517234B2 (enExample)
EP (1) EP2968310A4 (enExample)
JP (1) JP2016512818A (enExample)
KR (1) KR20150142691A (enExample)
CN (1) CN105358149A (enExample)
MX (1) MX2015013155A (enExample)
WO (1) WO2014149848A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107260694A (zh) * 2017-06-14 2017-10-20 广西大海阳光药业有限公司 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂
CN111675717A (zh) * 2020-06-21 2020-09-18 兰州理工大学 粉防己单体化合物及其提取方法和用途
WO2021036884A1 (zh) * 2019-08-23 2021-03-04 华东理工大学 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576077B2 (en) 2015-03-23 2020-03-03 Southwest Research Institute Pharmaceutical salt forms of Cepharanthine and Tetrandrine
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN114159438B (zh) * 2021-11-30 2023-07-18 首都医科大学附属北京安定医院 海兰地嗪及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187123A (zh) * 1995-04-11 1998-07-08 马萨诸塞眼科耳科诊所 眼炎治疗
CN102898433A (zh) * 2012-09-26 2013-01-30 中国医药研究开发中心有限公司 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569852A (en) * 1983-08-23 1986-02-11 Warner-Lambert Company Maintenance of flavor intensity in pressed tablets
JPH0678232B2 (ja) * 1986-03-07 1994-10-05 株式会社ツムラ アンジオテンシンｉ転換酵素阻害剤
JPH0678231B2 (ja) * 1986-03-08 1994-10-05 株式会社ツムラ 血液粘度低下剤
JPH0733388B2 (ja) * 1987-01-22 1995-04-12 株式会社ツムラ 新規アルカロイド
JPH02243627A (ja) * 1989-03-16 1990-09-27 Tsumura & Co 狭心症治療薬
US5332747A (en) 1989-09-28 1994-07-26 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells
US6911454B1 (en) 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US5025020A (en) 1989-09-28 1991-06-18 Cancer Biologics Of America, Inc. Use of tetrandrine and its derivatives to treat malaria
JPH0499723A (ja) * 1990-08-17 1992-03-31 Kaken Shiyouyaku Kk ウイルス・ゲノム不活化剤
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US6218541B1 (en) 1999-06-28 2001-04-17 Cba, International, Inc. Method for extracting bisbenzylisoquinolines
IL144760A0 (en) * 1999-12-08 2002-06-30 Pharmacia Corp Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US20050245559A1 (en) * 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
MX2009000923A (es) * 2006-08-04 2009-03-09 Agi Therapeutics Res Ltd Metodos para tratar cuando menos una condicion que tiene receptor de mt1, receptor de 5ht2b, y actividad de canal de calcio tipo l.
AU2009215514B9 (en) * 2008-02-20 2014-01-30 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
EP2241561A1 (en) 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound
WO2011056965A1 (en) 2009-11-05 2011-05-12 Cba International, Inc. Method for extracting and purifying bisbenzylisoquinolines
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
CN104955330A (zh) * 2012-09-13 2015-09-30 Cba制药有限公司 粉防己碱药物制剂及方法
JP2015531355A (ja) * 2012-09-28 2015-11-02 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 腫瘍治療のための薬剤組成物及びその適用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187123A (zh) * 1995-04-11 1998-07-08 马萨诸塞眼科耳科诊所 眼炎治疗
CN102898433A (zh) * 2012-09-26 2013-01-30 中国医药研究开发中心有限公司 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YI-CHAO HSU等: "Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis", 《JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107260694A (zh) * 2017-06-14 2017-10-20 广西大海阳光药业有限公司 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂
WO2021036884A1 (zh) * 2019-08-23 2021-03-04 华东理工大学 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用
CN111675717A (zh) * 2020-06-21 2020-09-18 兰州理工大学 粉防己单体化合物及其提取方法和用途

Also Published As

Publication number Publication date
US20180298022A1 (en) 2018-10-18
US10815243B2 (en) 2020-10-27
WO2014149848A1 (en) 2014-09-25
KR20150142691A (ko) 2015-12-22
MX2015013155A (es) 2016-04-04
US20140275137A1 (en) 2014-09-18
US20170050976A1 (en) 2017-02-23
US10023584B2 (en) 2018-07-17
EP2968310A1 (en) 2016-01-20
US9517234B2 (en) 2016-12-13
US20170050975A1 (en) 2017-02-23
EP2968310A4 (en) 2017-01-11
JP2016512818A (ja) 2016-05-09

Similar Documents

Publication Publication Date Title
CN114340608B (zh) 一种药物组合物及其应用
US10815243B2 (en) Tetrandrine family pharmaceutical formulations and method
RU2685730C1 (ru) Составы соединений азаиндола
RU2668882C2 (ru) Жидкая фармацевтическая композиция
BG62843B1 (bg) Орални течни фармацевтични състави, съдържащи пароксетинрезинат
JP2014503512A (ja) エンケファリナーゼ阻害剤の新規投与形態
US20140275139A1 (en) Mdr method and products for treating hiv/aids
CN104955330A (zh) 粉防己碱药物制剂及方法
CN108285431B (zh) 一种吡非尼酮有关物质及其制备方法和用途
JP2006528949A5 (enExample)
JP6549428B2 (ja) 経口組成物
CN111372572B (zh) 包含丹皮酚和罗布麻宁的液体制剂
KR100746444B1 (ko) 설사-우세형 과민성 대장 증후군의 치료제
CN111233877B (zh) 一种加兰他敏帕莫酸盐及其制备方法
RU2745985C1 (ru) Антикоронавирусный терапевтический агент - замещенный 7-гидрокси-3,4,12,12а-тетрагидро-1H-[1,4]оксазино[3,4-c]пиридо[2,1-f][1,2,4]триазин-6,8-дион для профилактики и лечения COVID-19
CN105357966A (zh) 提高药物和膳食补充剂的生物利用度的方法和产品
CN102920716B (zh) 复方抗球虫药物磺胺氯吡嗪钠溶液的制备方法
WO2016130043A1 (ru) Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в
US20140275138A1 (en) Method and products for treating diabetes
CN117752681B (zh) 复方丁香罗勒制剂的改进
CN115227658A (zh) 一种氨己烯酸固体制剂组合物
RU2574397C1 (ru) Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в
HK40063844B (zh) 一种药物组合物及其应用
JP2016514143A (ja) 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物
JP2008074820A (ja) インフルエンザ予防用若しくは治療用の経口薬又は健康食品

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160224

RJ01 Rejection of invention patent application after publication